Экспериментальное изучение фармакокинетики и метаболизма нового фармакологического препарата дилепт
![Диссертация: Экспериментальное изучение фармакокинетики и метаболизма нового фармакологического препарата дилепт](https://westud.ru/work/2524280/cover.png)
Диссертация
Существуют несколько типов эстераз с соответстующей специфической активностью, что может объяснить различия, наблюдаемые между видами экспериментальных животных. Например, производное оксиметил-кумариновой кислоты и опиоидного пептида- энкефалина образуют циклическое про-активное соединение. Это вещество относительно стабильно в плазме человека и лошади (Уг более 2-х часов) и гораздо менее… Читать ещё >
Содержание
- ВВЕДЕНИЕ.'
- ГЛАВА I. ЛИТЕРАТУРНЫЙ ОБЗОР
- 1. 1. Аналитические методы определения пептидов и их производных
- 1. 1. 1. Иммунохимические методы анализа
- 1. 1. 2. Хроматография аминокислот и пептидов
- 1. 1. 2. 1. Газовая хроматография пептидов
- 1. 1. 2. 2. Методы*жидкостной хроматографии пептидов
- 1. 1. 2. 2. 1. Тонкослойная хроматография
- 1. 1. Аналитические методы определения пептидов и их производных
- 1. Г. 2.2.2. Высокоэффективная жидкостная хроматография,
- 1. 1. 2. 3. Методы детектирования пептидов в высокоэффективной * жидкостной хроматографии
- 1. 1. 2. 3. 1. Спектрофотометрическое детектирование в ультрафиолетовой области спектра.18 «
- 1. 1. 2. 3. 2. Флуориметрические детекторы
- 1. 1. 2. 3. 3. Электрохимические детекторы
- 1. 1. 2. 4. Высокоэффективная жидкостная хроматография — масс-спектрометрия
- 1. 2. Фармакокинетика пептидов при различных способах введения
- 1. 2. 1. Фармакокинетика пептидов при парентеральном введении
- 1. 2. 1. 1. Внутривенное введение пептидов. Энзиматическая устойчивость пептидов
- 1. 2. 1. 2. Подкожное и внутримышечное введение пептидов
- 1. 2. 2. Альтернативные пути введения пептидов. Биодоступность пептидов, проникающих через слизистые оболочки
- 1. 2. 2. 1. Ингаляционное введение
- 1. 2. 2. 2. Интраназальное введение
- 1. 2. 2. 3. Трансдермальное введение
- 1. 2. 2. 4. Транссклеральный (окулярный) путь введения
- 1. 2. 2. 5. Буккальный/сублингвальный пути введения пептидов
- 1. 2. 1. Фармакокинетика пептидов при парентеральном введении
- 1. 1. 2. 3. Методы детектирования пептидов в высокоэффективной * жидкостной хроматографии
- I. 3. Проникновение пептидов через гематоэнцефалический барьер
- 2. 1. Реактивы и материалы
- 2. 1. 1. Исходные вещества
- 2. 1. 2. Реактивы
- 2. 1. 3. Средства измерений
- 2. 1. 4. Вспомогательные устройства
- 2. 1. 5. Приготовление растворов и буферов
- 2. 2. Способы введения и сбор биологических проб
- 2. 2. 1. Изучение фармакокинетики и метаболизма дилепта в опытах in vivo
- 2. 2. 1. 1. Введение препарата и отбор проб
- 2. 2. 1. 2. Подготовка биологических проб (плазма крови) к анализу
- 2. 2. 2. Изучение проникновения дилепта через ГЭБ
- 2. 2. 2. 1. Введение препарата и отбор проб
- 2. 2. 2. 2. Подготовка биологических проб (мозг) к анализу
- 2. 2. 1. Изучение фармакокинетики и метаболизма дилепта в опытах in vivo
- 2. 3. 1. Введение препарата и отбор проб
- 2. 3. 2. Подготовка биологических проб (моча) к анализу
- 2. 5. 1. Параметры ГХ-МС анализа дилепта и его предполагаемых метаболитов
- 2. 5. 2. Параметры ВЭЖХ-МС анализа дилепта и его предполагаемых метаболитов
- 2. 5. 3. Количественный анализ дилепта и его метаболитов методом ВЭЖХ-МС/МС
- 2. 5. 3. 1,Определение градуировочных зависимостей
- 2. 5. 3. 2. Установление метрологических характеристик метода
- 2. 5. 4. Статистический анализ полученных результатов
- 3. 1. Методы хромато-масс-спектрометрического анализа
- 3. 2. Экспериментальное изучение биологической стабильности дипептидного соединения дилепт
- 3. 2. 1. Изучение биологической стабильности дилепта в модельных опытах
- 3. 2. 2. Изучение биологической стабильности дилепта в опытах in vivo
- 3. 3. Экспериментальная фармакокинетика фармакологического препарата дилепт при разных путях введения
- 3. 3. 1. Фармакокинетика дилепта после внутривенного введения
- 3. 3. 2. Фармакокинетика дилепта после перперорального введения субстанции и таблеток
- 3. 3. 3. Изучение фармакокинетики идентифицированных метаболитов дилепта, обнаруженных в плазме крови крыс, после введения субстанции и таблеточной массы дилепта
- 3. 4. Изучение проницаемости дилепта и его активного метаболита — N-капроил-Ь-пролил-Ь-тирозина через гематоэнцефалический барьер
- 3. 5. Изучение экскреции дилепта к его метаболитов с мочой крыс
Список литературы
- Nemeroff С.В., Bissette G. Neuropeptides, dopamine and schizophrenia.// Ann. N.Y. Acad. Sci. 1992. -V. 668 -p. 273−291.
- Nemeroff C.B. Neurotensin: perchance an endogenous neuroleptic?// Biol. Psychiatry. 1980- V. 15, № 2. — p. 283−302.
- Nemeroff C.B., Levant В., Myers В., Bissette G. Neurotensin, antipsychotic drugs and schizophrenia. // Ann. N.Y. Acad. Sci. 1992. — V. 668. — p. 147−156.
- Richelson E., Boules M., Fredrickson P. Neurotensin agonists: possible drugs for treatment of psychostimulant abuse.// Life Sci. 2003. — V. 73. — p. 679 — 690.
- Гудашева T.A., Зайцева Н. И., Бондаренко H.A. и др.// Хим. фарм. журн.1997, № 11.-С. 10−16.
- Gudasheva Т.A., Voronina Т.А., Ostrovskaya R.U. et al.// J.Med.Chem.1998.-V. 41. -p. 284−290.
- Ретюнская М.В., Гузеватых J1.C., Бондаренко Н. А. и др. Медиаторный анализ механизма действия атипичного нейролептика дипептидной структуры Дилепта.// Бюлл. экспер. биол. и мед. 2003. — Т. 136, № 11. — С. 527−543.
- Островская Р.У., Ретюнская М. В., Гузеватых J1.C. и др. Трипептоидный аналог нейротензина дилепт сочетает нейролептическую активность с положительным мнемотропным действием.// Экспер. и клин, фарам. 2005. -Т. 68, № 1.-С. 3−6.
- Наглядная иммунология.// Г.-Р. Бурместер, А. Пецутто. М.: БИНОМ. Лаборатория знаний. Пер. с англ. — 2007. — СС. 320.
- Jadric R., Hasic S., Kiseljakovic E., Winterhalter-Jadric M. Comparison of trazodone, diazepame and dibenzepine influences on rat brain beta-endorphinscontent.// Bosn. J. Basic Med. Sci. 2007. — V. 7. — p. 222−225i
- Bowsher R.R., Lynch R.A., Brown-Augsburger P., Santa, P.F. et. al. Sensitive RIA for the specific determination of insulin lispro.// Clin. Chem. 1999. — V. 45. -p. 104−110.
- Goetze J.P., Kastrup J., Pedersen F., Rehfeld J.F. Quantification of pro-B-type natriuretic peptide and its products in human plasma by use of an analysis independent of precursor processing.// Clin. Chem. 2002. — V. 48. — p. 1035−1042.
- Bryl W., Miczke A. et. al. Assessment of blood pressure and endothelin-1 plasma concentration in young, hypertensive patients after treatment with angiotensin converting enzyme inhibitor. // Pol. Merk. Lekar. 2005. — V. 107, № 48. — p. 524 -6.
- Riedel F., Zaiss I., Herzog, D. et. al. Serum levels of interleukin-6 in patients with primary head and neck squamous cell carcinoma.// Anticancer Res. 2005. — V. 25, № 4.-p. 2761 -2765.
- Schmidt R., Steinhilber W., Ruppert C. et. al. An ELISA technique for quantification of surfactant apoprotein (SP)-C in bronchoalvcolar lavage fluid. // Am. J. Respir. Crit. Care Med. 2002. V. 165. — p. 470 — 474.
- Sinha M.K., Songer Т., Xiao Q. et. al. Analytical validation and biological evaluation of a high molecular-weight adiponectin ELISA.// Clin. Chem. 2007. — V. 53.-p. 2144−2151.
- Bao J., Tu Z., Wang J., Ye F. et.al. A novel accurate rapid ELISA for detection of urinary connective tissue growth factor, a biomarker of chronic allograft nephropathy.// Transplant Proc. 2008. — V.40. — p. 2361−2364.
- El-Haggar S., El-Ashmawy S., Attia A., Mostafa T. Beta-endorphin in serum and seminal plasma in infertile men.// Asian. J. Androl. 2006 — V. 8. — p. 709−712.
- Miiller S., Но В., Gambus P. et. al. An HPLC/RIA method for dynorphin Al-13 and its main metabolites in human blood.// Journal of Pharmaceutical and Biomedical Analysis. 1997. — V. 16, № 1. — p. 101 -109.
- Handbook of Affinity Chromatography.// Hage S David. CRC Press. 2006. -pp 944.
- Maidment N.T., Brumbaugh D.R., Rudolph V.D. et. al. Microdialysis of extracellular endogenous opioid peptides from rat brain in vivo.// Neuroscience. -1989. V. 33.-p. 549−557.
- Aubry A.F., Caude M., Rosset R. Separation and identification of dipeptides in a hydrolyzed brain extract.// Chromatographia. 1992. — V. 33. — p. 11−12.
- Caprioli R.M., Seifert W.E., Sutherland D.E. Polypeptide sequencing: use of dipeptidylaminopeptidase I and gas chromatography-mass spectrometry.// Biochem. Biophys. Res. Commun. 1973. — V. 55. — p. 67 — 75
- Caprioli R.M., Seifert W.E. Hydrolysis of polypeptides and proteins utilizing a mixture of dipeptidylaminopeptidases with analysis by GC/MS.// Biochem. Biophys. Res. Commun. 1975. — V. 64. — p. 295−303.
- Seifert W.E., McKee R.E., Beckner C.F., Caprioli R.M. Characterization of mixtures of dipeptides by gas chromatography/mass spectrometry.// Anal. Biochem. 1978.-V. 88.-p. 149−161.
- Kingston E.E., Duffield A.M. Plasma amino acid quantitation using gas chromatography chemical ionization mass spectrometry and 13C amino acids as internal standards.// Biomed. Mass. Spectrom. 1978. — V. 5. — p. 621−626.
- Samy T.S., Hahm K.S., Modest E.J. et. al. Primary structure of macromomycin, an antitumor antibiotic protein.// J. Biol. Chem. 1983. — V. 258. -p. 183−191.
- MacKenzie S.L., Corbett M.E., Scrimgeour C.M., Watt P.W. Use of tert.-butyldimethylsilyl derivatives for gas chromatographic-mass spectrometric analysis of dipeptides.// J. Chromatogr. 1987. — V. 419. — p. 263−270.
- Mawhinney T.P., Robinett R.S., Atalay A., Madson M.A. Gas-liquid chromatography and mass spectral analysis of mono-, di- and tricarboxylates as their tert.-butyldimethylsilyl derivatives.// J. Chromatogr. 1986. — V. 361. — p. 117−130.
- Seifert W.E., McKee R.E., Beckner C.F., Caprioli R.M. Characterization of mixtures of dipeptides by gas chromatography/mass spectrometry.// Anal. Biochem. 1978.-V. 88.-p. 149−161
- Krutzsch H.C. Polypeptide Sequence Analysis Using Gas Chromatography-Mass Spectrometry.// Methods of Protein Microcharacterization. Humana Press. -1986.-V. 2.-p. 381−401.
- Monlar-Perl I., Katona Z.F. GC-MS of amino acids as their trimethylsilyl/t-butyldimethylsilyl derivatives: in model solutions III.// Chromatographia (suppl.). -2000.-V. 51.-p. 228−236.
- Patzold R., Theis C., Bruckner H. Gas-chromatographic separation of stereoisomers of dipeptides.// Chirality. 2006. — 18. — p. 551−557.
- Husek P. Rapid derivatization and gas chromatographic determination of amino acids.// J. Chromatogr. 1991. — V. 552. — p. 289−299.
- Husek P., Sweeley C.C. Gas chromatographic separation of protein amino acids in four minutes.// J. High Resolut. Chromatogr. 1991. — V. 14. — p. 751
- Husek P. Amino acid derivatization and analysis in five minutes.// FEBS Lett. 1991.-V. 280.-p. 354−356.
- Bhushan R., Martens J. Amino acids and their derivatives. // Handbook of Thin-Layer Chromatography. Third Edition. Revised and Expanded./ Sherma J, Fried В (eds). Marcel Dekker. New York. 2003. — p. 373−415.
- Bhushan R and Martens J. Peptides and proteins. // Handbook of Thin-Layer Chromatography. Third Edition. Revised and Expanded./ Sherma J, Fried В (eds). Marcel Dekker. New York. 2003. — p. 749−766.
- П. Садек. Растворители для ВЭЖХ.// М.: БИНОМ. Лаборатория знаний. -2006.-сс. 295−296.
- Yoshida Т. Peptide separation in normal phase liquid chromatography.// Anal Chem. 1997. -V. 69, № 15.-p. 3038−3043.
- Yoshida T. Calculation of peptide retention coefficients in normal-phase liquid chromatography.// J Chromatogr A. 1998 — V. 8081, № 2. — p. 105−112.
- Yoshida Т., Okada T. Peptide separation in normal-phase liquid chromatography. Study of selectivity and mobile phase effects on various columns. J. Chromatogr. A. 1999. — V. 840, № 1. — p. 1 -9.
- Molnar I., Horvath C. Separation of Amino Acids and Peptides on Non-Polar Stationary Phases by High-Performance Liquid Chromatography.// J. Chromatogr. -1977.-V. 142.-p. 623−640.
- Meek J.L. Prediction of peptide retention times in high-pressure liquid chromatography on the basis of amino acid composition.// Proc. Natl. Acad. Sci. U.S.A. 1980. — V. 77. — p. 1632−1636.
- Meek J.L., Rossetti Z.L. Factors affecting retention and resolution of peptides in high-performance liquid chromatography.// J. Chromatogr. 1981. — V.211. — p. 15−28.
- Browne C.A., Bennett H.P.J., Solomon S. The isolation of peptides by highperformance liquid chromatography using predicted elution positions.// Anal. Biochem. 1982. — V. 124. — p. 201−2Q8.
- Sasagawa Т., Okuyama Т., Teller D.C. Prediction of peptide retention times in reversed-phases high-performance liquid chromatography during linear gradient elution.// J.Chromatogr. 1982. — V. 240. — p. 329−340.
- Blondelle S.E., Butter K., Houghten R.A. Evalution of peptide-peptide interactions using reversed-phase high-performance liquid chromatography.// J. Chromatogr. 1992. — V. 625. — p. 199−206.
- Lebl M. Observation of a conformational effect in peptide molecule by reversed-phase high-performance liquid chromatography.// J. Chromatogr. 1993. -V. 644.-p. 285−287.
- Mentlein R., Lucius R. Methods for the investigation of Neuropeptide Catabolism and Stability in vitro.// Brain. Res. Protocols. 1997. — V. 1. — p. 237 246.
- Детекторы для хроматографии./ Бражников В. В. М.: Машиностроение. — 1992.-с. 320.
- Практическая высокоэффективная жидкостная хроматография./ Стыскин Е. Л., Ициксон Л. Б., Брауде Е. В. М.: Химия. — 1986. — с. 288.
- Shippy S.A., Jankowski J.A., Sweedler J.V. Analysis of Trace Level Peptides Using Capillary Electrophoresis with UV Laser-Induced Fluorescence.// Anal. Chim. Acta. 1995. — V. 307. — p. 163−171.
- Freed A.L., Audus K.L., Lunte S.M. Investigation of the metabolism of substance P at the blood-brain barrier using capillary electrophoresis with laser-induced fluorescence detection.// Electrophoresis. 2001. — V.22. — p. 3778−84.
- Shangguan D., Zhao Y., Han H. et. al. Derivatization and fluorescence detection of amino acids and peptides with 9-fluorenylmethyl chloroformate on the surface of a solid adsorbent.// Anal. Chem. 2001. — V. 73. — p. 2054−2057.
- Kai M., Ohkura Y. Fluorescence derivatization of bioactive peptides for highperformance liquid chromatography.// Trends Anal. Chem. 1987. — V. 6. — p. 116−120.
- Zhang G., Kai M., Ohkura Y. Determination of Seven Opioid Peptides in Rat Brain by High Performance Liquid Chromatography with On-Line Postcolumn Fluorescence Derivatization.// Anal. sci. 1990. — V. 6. — p. 671−676.
- Woltman S.J., Alward M.R., Weber S.G. Rotating ring-disk electrode study of copper (II) complexes of the model peptides triglycine, tetraglycine, and pentaglycine.//Anal. Chem. 1995. — V. 67. — p. 541−551.
- Shen H., Witowski S.R., Boyd B.W., Kennedy R.T. Detection of peptides by precolumn derivatization with biuret reagent and preconcentration on capillary liquid chromatography columns with electrochemical detection. Anal. Chem. 1999. — V. 71.-p. 987−994.
- Woltman S.J., Shi F., Weber S.G.// Peptides. Proceedings of the European Peptide Symposium. UK. 1998. — p. 919.
- Kaudewitz H. Mass spectrometr as HPLC detector.// Labor. Praxis. 1992. V.16, № 7. — p. 730−733.
- Yamashita M., Fenn J.B. Electrospray ion source. Another variation on the free-jet theme.// J. Phys. Chem. 1984. — V. 88. — p. 4451−4459.
- Yamashita M., Fenn J.B. Negative ion production with the electrospray ion source.// J. Phys. Chem. V. 88. — p. 4671−4675.
- Meng C.K., Mann M., Fenn J.B. Electrospray ionization of some polypeptidesand small proteins.// Proceedings of the 36th American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics. USA. 1988, p. 711−772.
- Fenn J.B., Mann M., Meng C.K. et. al. Electrospray ionization for mass spectrometry of large biomolecules.// Science. 1989. — V. 246. — p. 64−71
- Karas M., Hillenkamp F. Laser desorption ionization of proteins with molecular masses exceeding 10,000 daltons. Anal. Chem. 1988. — V. 60. — p. 22 992 301.
- Wilm M., Shevchenlco A., Houthaeve T. et. al. Femtomole sequencing of proteins from polyacrylamide gels by nano-electrospray mass spectrometry.// Nature.- 1996. V. 379. — p. 466−469.
- Andresn P.E., Emmett M.R., Caprioli R.M. Micro-electrospray: zeptomole/attomole per microlitre sensitivity for peptides.// J. Am. Soc. Mass Spectrom. 1994. — V. 5. — p. 867−869.
- Kebarle P., Tang L. From ions in solution to ions in the gas phase. The mechanism of electrospray mass spectrometry.// Anal. Chem. 1993. — V. 65, № 22.- p. A972-A986.
- Karas M., Bahr U., Diilcks T. Nano-electrospray ionization mass spectrometry: addressing analytical problems beyond routine.// J. Anal. Chem. 2000. — V. 366. -p. 669−676.
- Wickremsinhe E.R., Singh G., Ackermann B.L. et. al. A review of nanoelectrospray ionization applications for drug metabolism and pharmacokinetics.// Curr. Drug. Metab. 2006. — V. 7. — p. 913−928.
- Нор С. E. С. A. Use of nano-electrospray for metabolite identification and quantitative absorption, distribution, metabolism and excretion studies.// Curr. Drug. Metab. 2006. — V. 7. — p. 557−563.
- Takats Z., Wiseman J.M., Gologan В., Cooks R.G. Mass spectrometry sampling under ambient conditions with desorption electrospray ionization.// Science. 2004. — V. 306. — p. 471−473.
- Nefliu M., Venter A., Cooks R.G. Desorption electrospray ionization and electrosonic spray ionization for solid- and solution-phase analysis of industrial polymers.// Chem. Commun. (Camb). 2006. — p. 888−890.
- Li L., Garden R.W., Sweedler J.V. Single-cell MALDI: a new tool for direct peptide profiling.// Trends Biotechnol. 2000. — V. 18. — p. 151−160.
- Li L., Romanova E.V., Rubakhin S.S. et. al. Peptide profiling of cells with multiple gene products: combining immunochemistry and MALDI mass spectrometry with on-plate microextraction.// Anal. Chem. 2000. — V. 72. — p. 3867−3874.
- Na D.H., DeLuca P.P., Lee K.C. Direct determination of the peptide content in microspheres by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.// Anal. Chem. 2004. — V. 76. — p. 2669−2673.
- Amini A., Nilsson E. Quantitative analysis of polypeptide pharmaceuticals by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.// J. Pharm. Biomed. Anal. 2008. — V. 46. — p. 411−417.
- Steel C., Henchman M. Understanding the quadrupole mass filter through computer simulation.// Journal of Chemical Education. 1998. — V. 75. — p. 10 491 054.
- Mamyrin B.A. Time-of-flight m^ss spectrometry (concepts, achievements, and prospects).// International Journal of Mass Spectrometry. 2001. — V. 206. — p. 251 266.
- Marshall A.G., Hendrickson C.L. Fourier transform ion cyclotron resonance detection: principles and experimental configurations.// International Journal of Mass Spectrometry-2002.-V. 215.-p. 59−75.
- Stafford G. Ion trap mass spectrometry: a personal perspective. J. Am. Soc. Mass Spectrom. 2002. V. 13. — p. 589−596.
- Hu Q., Noll R.J., Li H., Makarov A. et. al. The Orbitrap: a new mass spectrometer.// J. Mass Spectrom. 2005. — V. 40. — p. 430143.
- Масс-спектрометрия в органической химии./ А. Т. Лебедев. М: БИНОМ. Лаборатория знаний. — 2003. — с. 493.
- John Н., Walden М., Schafer S. et. al. Analytical procedures for quantification of peptides in pharmaceutical research by liquid chromatography-mass spectrometry.//Anal. Bioanal. Chem. 2004. — V. 378. — .p. 883−897.
- Qin W., Zhang Z., Tian Y., Xu F. et. al. Rapid quantification of lisinopril in human plasma by liquid chromatography/tandem mass spectrometry. Biomed. Chromatogr. 2007. — V. 21. — p. 415−421.
- Hortin G.L. The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome.// Clin. Chem'. 2006. — V. 52. — p. 1223−1237.
- Marvin L.F., Roberts M.A., Fay L.B. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry in clinical chemistry.// Clin. Chim. Acta. 2003. — V. 337. — p. 11−21.
- Chernushevich I.V., Loboda A.V., Thomson, B.A. An introductionto quadrupole-time-of-flight mass spectrometry.// J. Mass. Spectrom. 2001. — V. 36. -p. 849−865.
- Wan H., Desiderio D.M.Quantification of DmtljDALDA in ovine plasma by on-line liquid chromatography/quadrupole time-of-flight mass spectrometry. Rapid Commun. Mass Spectrom. 2003. — V. 17. — p. 538−546.
- Wan H., Umstot E.S., Szeto H.H. et. al. Quantitative analysis of Dmt (l).DALDA in ovine plasma by capillary liquid chromatography-nanospray ion-trap mass spectrometry.// J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. -2004.-V. 803.-p. 83−90.
- Paul W., Steinwedel Z.Z. A new mass spectrometer without magnetic field.// Naturforsh. 1953. — V. 8a. — p. 448−450.
- Paul W., Reinhard H.P., Zahn U.V. The electric mass filter as mass spectrometer and isotope separator.// Zi Phys. 1958. — V. — 152. — p. 143−182.
- Feng W.Y., Chan K.K., Covey J.M. Electrospray LC-MS/MS quantitation, stability, and preliminary pharmacokinetics of bradykinin antagonist polypeptide B201 (NSC 710 295) in the mouse.// J. Pharm. Biomed. Anal. 2002. — V. 28. — p. 601−612.
- Клюев H.A., Бродский E.C. Современные методы масс-пектрометрического анализа органических соединений.// Рос. хим. журн. (Ж. Рос. хим. об-ва им. Д.И. Менделеева). 2002. — Т. XLVI, № 4. — с. 57.
- Appolpnova S.A., Shpak A.V., Semenov V.A. Liquid chromatography-electrospray ionization ion trap mass spectrometry for analysis of mesocarb and its metabolites in human urine.// J. Chromatogr. B. 2004. — V. 800. — p. 281−289.
- Fang C.B., Wan X.C., Tan H.R., Jiang C.J. Identification of Isoflavonoids in several kudzu samples by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.// J. Chromatogr. Sci. 2006. V. 44.-p. 57−63.
- John H., Forssmann W.G. Determination of the disulfide bond pattern of the endogenous and recombinant angiogenesis inhibitor endostatin by mass spectrometry.// Rapid.Commun. Mass Spectrom. 2001. — V. 15. — p. 1222−1228.
- Van Berkel G.J., Glish G. Li, McLuckey S.A. Electrospray Ionization Combined with Ion Trap Mass-Spectrometry. Anal. Chem. 1990. — V. 63. — p. 1284−1295.
- Mihailova A., Karaszewski В., Hauser R. et. al. Identification of neuropeptides in rat brain rhinencephalon.// J. Sep. Sci. 2007. — V. 30. — p. 249−256.
- Vergote V., Baert В., Vandermeulen E. et. al. LC-UV/MS characterization and DOE optimization of the iodinated peptide obestatin.// J. Pharm. Biomed. Anal. -2008.-V. 46.-p. 127−136.
- Graham C., Irvine A.E., McClean S. et. al. Peptide tyrosine arginine, a potent immunomobulatory peptide isolated and structurally characterized from the skin secretions of the dusk gopher frog, Rana sevosa.// Peptides 2005. — V. 26. — p. 737 743.
- Lupi A., Messana I., Denotti G. et. al. Identification of the human salivary cystatin complex by the coupling of high-performance liquid chromatography and ion-trap mass spectrometry.// Proteomics. 2003. — V. 3. — p. 461- 467.
- Makarov A. Electrostatic axially harmonic orbital trapping: a high-performance technique of mass analysis.// Anal. Chem. 2000. — V. 72. — p. 11 561 162.
- Hardman M., Makarov A.A. Interfacing the orbitrap mass analyzer to an electrospray ion source.// Anal. Chem. 2003. — V. 75. — p. 1699−1705.
- Krause E., Wenschuh H., Jungblut P.R. The dominance of arginine-containing peptides in MALDI-derived tryptic mass fingerprints of proteins.// Anal. Chem. -1999-V. 71.-p. 4160−4165.
- King R., Bonfiglio R., Fernandez-Metzler C. et. al. Mechanistic investigation of ionization suppression in electrospray ionization.// J. Am. Soc. Mass Spectrom. -2000.-V. 11.-p. 942−950.
- Sterner J.L., Johnston M.V., Nicol G.R., Ridge D.P. Signal suppression in electrospray ionization fourier transform mass spectrometry of multi-component samples.// J. Mass Spectrom. V. 2000. — V. 35. — p. 385−391.
- Bonfiglio R., King R.C., Olah T.V., Merkle K. The effects of sample preparation methods on the variability of the electrospray ionization response for model drug compounds. Rapid Commun. Mass Spectrom. 1999. — V. 13. — p. 11 751 185.
- Visser N.F.C., Lingeman H., Irth H. Sample preparation for peptides and proteins in biological matrices prior .to liquid chromatography and capillary zone electrophoresis.// Anal. Bioanal. Chem. 2005. — V. 382. — p. 535−558.
- Johnson, К. L., Mason C.J., Muddiman D.C., Eckel J.E. Analysis of the low molecular weight fraction of serum by LC-dual ESI-FT-ICR mass spectrometry: precision of retention time, mass, and ion abundance.// Anal. Chem. 2004. — V. 76. -p. 5097−5103.
- Zheng X., Baker H., Hancock W.S. Analysis of the low molecular weight serum peptidome using ultrafiltration and a hybrid ion trap-Fourier transform mass spectrometer.// J. Chromatogr. A. 2006. — V. 1120. — p. 173−184.
- Aristoteli L.P., Molloy M.P., Baker M.S. Evaluation of endogenous plasma peptide extraction methods for mass spectrometric biomarker discovery.// J. Proteome Res. 2007. — V. 6.-p. 571−581.
- Kamphorst J.J., van der Heijden R., DeGroot et. al. Profiling of endogenous peptides in human synovial fluid by NanoLC-MS: method validation and peptide identification.// J. Proteome Res. 2007. — V. 6. — p. 4388−4396.
- Valaskovic G.A., Kelleher N.L. Miniaturized formats for efficient mass spectrometry-based proteomics and therapeutic development. //Curr. Top. Med. Chem.-2002.-V. 2.-p. 1−12.
- Cutillas P.R., Norden A.G., Cramer R. et. al. Detection and analysis of urinary peptides by on-line liquid chromatography and mass spectrometry: application to patients with renal Fanconi syndrome.// Clin. Sci. (Lond). 2003. V. 104. — p. 483 490.
- Dai S., Dou G., Qiang X. et. al. Pharmacokinetics of sifuvirtide, a novel anti-HIV-1 peptide, in monkeys and its inhibitory concentration in vitro.// Acta Pharmacol. Sin. 2005. — V. 26. — p. 1274−1280.
- Aristoteli L.P., Molloy M.P., Baker M.S. Evaluation of endogenous plasma peptide extraction methods for mass spectrometric biomarker discovery.// J. Proteome Res.-2007.-V. 6.-p. 571−581.
- Dettmer K., Hanna D., Whetstone P. et. al. Autism and urinary exogenous neuropeptides: development of an on-line SPE-HPLC-tandem mass spectrometrymethod to test the opioid excess theory.// Anal. Bioanal. Chem. 2007. — V. 388. — p. 1643−1651.
- Hernandez E., Benavente F., Sanz-Nebot V., Barbosa J. Analysis of opioid peptides by on-line SPE-CE-ESI-MS.// Electrophoresis. 2007. V. 28. — p. 39 573 965.
- Chen X., Gardner E.R., Figg W.D. Determination of the cyclic depsipeptide FK228 in human and mouse plasma by liquid chromatography with mass-spectrometric detection.// J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci., -2008-V. 865.-p. 153−158.
- Kjellstrom S., Jensen O.N. In situ liquid-liquid extraction as a sample preparation method for matrix-assisted laser desorption/ionization MS analysis of polypeptide mixtures.// Anal. Chem. 2003. — V. 75. — p. 2362−2369.
- Selby C. Interference in immunoassay.// Ann. Clin. Biochem. 1999. — V. 36, № 6.-p. 704−721.
- Hollenberg N.K. Implications of species difference for clinical investigation: studies on the renin-angiotensin system.// Hypertension. 2000. — V. 35. — p. 150 -154.
- Lalu K., Lampelo S., Nummelin-Kortelainen M., Vanha-Perttula T. Purification and partial characterization of aminopeptidase A from the serum of pregnant and non-pregnant women.// Biochim. Biophys. Acta 1984. — V. 789. — p. 324−333.
- Tang L., Persky A.M., Hochhaus G., Meibohm B. Pharmacokinetic aspects of biotechnology products.// J. Pharm. Sci. 2004. — V. 87, № 11. — p. 1351 -1356.
- Brownson E.A., Abbruscato T.J., Gillespie T.J., Hruby V.J., Davis T.P. Effect of peptidases at the blood brain barrier on the permeability of enkephalin.// J. Pharmacol. Exp. Ther. 1994. — V. 270. — p.675- 680.
- Vijayaraghavan J., Scicli A.G., Carretero O.A. et. al. The hydrolysis of endothelins by neutral endopeptidase 24.11 (enkephalinase).// J. Biol. Chem. 1990. -V. 265.-p. 14 150−14 155.
- Molineaux C.J., Ayala J.M. An inhibitor of endopeptidase-24.15 blocks the degradation of intraventricularly administered dynorphins.// J. Neurochem. Aug. -1990. V. 55. — p. 611- 618.
- Checler F., Vincent J.P., Kitabgi P. J. Biol. Chem. 1986. — V. 261. — p. 11 274−11 281.
- Checler F., Barelli H., Kitabgi P., Vincent J.P.// Biochimie. 1988. — V. 70. -p. 75−82.
- L.J. Greene, A.C. Spadaro, A.R. Martins et. al. Brain endo-oligopeptidase В: a post-proline cleaving enzyme that inactivates angiotensin I and II.// Hypertension. -1982.-V. 4.-p. 178−184.
- Solhonne В., Gros C., Pollard H., Schwartz J.C. Major localization of aminopeptidase M in rat brain microvessels.// Neuroscience. 1987. -.V. 22. — p. 225−232.
- Bausback H.H., Churchill L., Ward P.E. Angiotensin metabolism by cerebral microvascular aminopeptidase A.// Biochem. Pharmacol. — 1988. — V. 37. — p. 155— 160.
- Hersh L. B. Characterization of Membrane-Bound Aminopeptidases from Rat Brain: Identification of the Enkephalin-Degrading Aminopeptidase.// Journal of Neurochemistry. 1985. — V. 44. — p. 1427−1435.
- Li X., Lou Z., Li X., Zhou W. Structure of human cytosolic X-prolyl aminopeptidase: a double Mn (II)-dependent dimeric enzyme with a novel three-domain subunit.// J. Biol. Chem. 2008. — V. 283, № 33. — p. 22 858−22 866. *
- Brecher P., Tercyak A., Gavras H., Chobanian A.V. Peptidyl dipeptidase in rabbit brain microvessels.// Biochim. Biophys. Acta 1978. — V. 526. — p.537−546.
- Benuck M., Berg M.J., Marks N. Met-enkephalin-Arg6-Phe7 metabolism: conversion to Met-enkcphalin by brain and kidney dipeptidyl carboxypeptidases.// Biochem. Biophys. Res. Commun. 1981. — V. 99. — p. 630 636.
- Song L., Wilk E., Wilk S., Healy D.P. Localization of immunoreactive glutamyl aminopeptidase in rat brain. Association with cerebral microvessels.// Brain. Res. 1993. — V. 606. — p. 286 -294.
- Warburton M.J., Bernardini F. Tripeptidyl peptidase-I is essential for the degradation of sulphated cholecystokinin-8 (CCK-8S) by mouse brain lysosomes.// Neurosci. Lett. -2002. V. 331.-p. 99−102.
- MacCumber M.W., Snyder S.H., Ross C.A. Carboxypeptidase E (enkephalin convertase): mRNA distribution in rat brain by in situ hybridization.// J. Neurosci.1990. V.10, № 8. — p.2850−60.
- Skidgel R.A. Basic carboxypeptidases: regulators of peptide hormone activity.//Trends Pharmacol. Sci. 1988. — V. 9. — p. 299−304.
- Adessi C., Soto C. Converting a peptide into a drug: strategies to improve stability and bioavailability.// Curr. Med. Chem. 2002. — V. 9. — p. 963−978.
- Colburn W. Peptide, peptoid, and protein pharmacokinetics/pharmacodynamics. In: Garzone, P., Colburn, W. and- Mokotoff, M. (eds), Peptides, Peptoids, and Proteins. Cincinnati, OH, Harvey Whitney Books.1991.-p. 94−115.
- Feng W.Y., Chan K.K., Covey J.M. Electrospray LC-MS/MS quantitation, stability, and preliminary pharmacokinetics of bradykinin antagonist polypeptide B201 (NSC 710 295) in the mouse.// J. Pharm. Biomed. Anal. 2002. — V. 28. — p. 601−612.
- Lambert L.H., Geertrui F.A. Vanhove L. Use of XMP-629 for the treatment of acne. European Patent № 1 648 491 (Al). XOMA technology LTD.- 2006.
- Besser D., Miiller В., Agricola I., Reissmann S. Synthesis of differentially protected N-acylated reduced pseudodipeptides as building units for backbone cyclic peptides.// J. Peptide Sci. 2000. — V. 6. — p. 130−138.
- Kaul R., Surprcnant S., Lubell. W.D. Systematic study of the synthesis of macrocyclic dipeptide (3-turn mimics possessing 8-, 9-, and 10- membered rings by ring-closing metathesis.// J. Org. Chem. 2005. — V. 70. — p. 3838−3844.
- Poteau R., Trinquier G. All-cis cyclic peptides.// J. Am. Chem. Soc. 2005. -V. 127.-p. 13 875−13 889.
- Nielsen Т.Е., Quement S.L., Meldal M. Solid-phase synthesis of bicyclic dipeptide mimetics by intramolecular cyclization of alcohols, thiols, amines, and amides with N-acyliminium intermediates.// Org. Lett. — 2005. V. 7. — p. 36 013 604.
- Liederer B.M., Fuchs Т., Velde D.V., Siahaan T.J., Borchardt R.T. Effccts of amino acid chirality and the chemical linker on the cell permeation characteristics of cyclic prodrugs of opioid peptides.// J. Med. Chem. 2006. — V. 49. — p. 1261−1270.
- Flora D., Mo H., Mayer J.P., Khan M.A., Yan L.Z. Detection and control of aspartimide formation in the synthesis of cyclic peptides.// Bioorg. Med. Chem. Lett. 2005. — V. 15. — p. 1065−1068.
- Che Y., Marshall G.R. Engineering cyclic tctrapeptides containing chimeric amino acids as preferred reverse-turn scaffolds.// J. Med. Chem. 2006. — V. 49. — p. 111−124.
- Arnott G., Clayden J., Hamilton S.D. Azabicyclic amino acids by stereoselective dearomatizing cyclization of the enolates of N-nicotinoyl glycine derivatives.// Org. Lett. 2006. — V. 8. — p. 5325−5328.
- Norgren A.S., Biittner F., Prabpai S., Kongsaeree P., Arvidsson P.I. 32-aminoacids in the design of conformationally homogeneous cyclo-peptide scaffolds// Org. Chem. 2006. — V.71. — p. 6814−6821.
- Gilon С., Halle D., Chorev M.,' Selinger Z., Byk G. Backbone cyclization: a new conformational constraint on peptides.// Biopolymers. 1991. — V. 31. — p. 745 750.
- Al-Obeidi F., Castrucci A.M.L., Hadley M.E., Hruby V.J. Potent and prolonged acting cyclic lactam analogues off a-melanotropin: design based on molecular dynamics.// J. Med. Chem. 1989. — V.32. — p. 555−2561.
- Charpentier В., Dor A., Roy P. et. al. Synthesis and binding affinities of cyclic and related linear analogues of CCK8 selective for central receptors.// J.Med. Chem. 1989. — V. 32.-p. 1184−1190.
- Бойко С.С., Жердев В. П. и соавт. Биодоступность ноопепта нового ноотропного препарата дипептидной структуры//Хим.-фарм. Журнал. ← 2004. -т. 38, № 12.-стр. 3−5.
- Бойко С.С., Жердев В. П. и соавт. Фармакокинетика лиофилизированной лекарственной формы ноопепта у крыс после внутривенного введения. Хим.-фарм. журн. — 2007. — т. 41, № 3. — стр. 6−8.
- Бойко С.С., Колыванов Г.Б и соавт. Экспериментальное исследование фармакокинетики триптофансодержащего дипептида ГБ-115.// Бюллетень экспериментальной биологии и медицины. 2007.- т. 144, № 9. — стр. 285−287.
- Hazel H., Szeto J.L., Lovelace G. et. al. In Vivo Pharmacokinetics of Selective (i-Opioid Peptide Agonists. //JPET. 2001. — V. 298. — p. 57−61.
- Kjolbye A. L., Carsten A. K. et. al. Pharmacological Characterization of the New Stable Antiarrhythmic Peptide Analog Ac-D-Tyr-D-Pro-D-Hyp-Gly-DAla-Gly-NH2 (ZP123): In Vivo and in Vitro Studies.// JPET. 2003. — V. 306. — p. 1191— 1199.
- Perni R.B.- Almquist, S.J. et. al. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis С virus NS3−4A serine protease.// Antimicrob. Agents Chemother. 2006. — V. 50,. — p. 899 — 909.
- Kiriyama A.- Fujita К et. al. Plasma pharmacokinetics and urinary and biliary excretion of a new potent tripeptide HIV-l protease inhibitor, KNI-272, in rats after intravenous administration. // Biopharm .Drug Dispos. 1994, — V. 15. — p. 617−626.
- Takeuchi Т., Tagawa, Y. et. al. Nonlinear pharmacokinetics of TAK-044, a new endothelin antagonist, in rats. Biopharm. Drug Dispos. 2001. — V. 22. — p. 221 -230 .
- Malik D.K., Baboota S., Ahuja A., Hasan S., Ali J. Recent advances in protein and peptide drug delivery systems.// Curr. Drug Deliv. 2007. — V. 4. — p. 141−151.
- Chen C., Pollack G.M. Development of a capillary zone electrophoresis assay to examine the disposition of D-pen2,5.enkephalin in rats. J. Chromatogr B. Biomed Appl. 1996. — V. 681. — p. 363−373.
- Chen C., Pollack G.M. Extensive biliary excretion of the model opioid peptide D-PEN2,5. enkephalin in rats.// Pharm. Res. 1997. — V. 14. — p. 345−350.
- Neilan C.L., Nguyen T.D., Schiller P.W., Pasternak G.W. Pharmacological characterization of the dermorphin analog Dmtl JDALDA, a highly potent and selective m -opioid peptide.// Eur. J. Pharmacol. 2001. — V. 419. — p. 15 — 23.
- Zhao G.M., Wu D. Soong Y. et al. Profound spinal tolerance after repeated exposure to a highly selective m -opioid peptide agonist: role of d -opioid receptors.// J Pharmacol. Exp. Ther. 2002. — V. 302. — p. 188 — 196.
- Verhoef J., Prins A., Veldhuis H.D., Witter A. H-Pro-3H.Leu-Gly-NH2: plasma profile and brain uptake following subcutaneous injection in the rat.// J. Neurochem.- 1982.-V. 38.-p. 1135−1138.
- Verhoef J.C., van den Wildenberg H.M. Des-enkephalin-gamma-endorphin: bioavailability in rats following the subcutaneous and intramuscular route of administration.//Regul. Pept. 1986. — V. 14.-p. 113−124.
- Verhoef J., van den Wildenberg, H. M. Des-enkephalin-gamma-endorphin (DE gamma E): pharmacokinetics in dogs after intravenous and subcutaneous administration.// Eur J. Drug Metab. Pharmacokinet. 1989. — V. 14. — p. 229−234.
- Weber S.J., Greene D.L., Hruby V.J. et. al. Whole body and brain distribution of 3H. cyclic [D-Pen2,D-Pen5] enkephalin after intraperitoneal, intravenous, oral and subcutaneous administration.// J. Pharmacol. Exp. Ther. 1992. — V. 263. — p. 13 081 316.
- Zhou X.H., Po A.L.W. Peptide and protein drugs. Therapeutic applications, absorption and parenteral administration.// Int. J. Pharmaceutics. 1991. — V.75. — p. 97−115.
- Frokjaer S., Hovgaard L. Pharmaceutical Formulation Development of Peptides and Proteins.// CRC Press. 2000. — p. 238.199.
- Wearley L.L. Recent progress in protein and peptide delivery by noninvasive routes.// Crit. Rev. Ther. Drug. Carrier, Syst. 1991. -V. 8. — p. 331−394.
- Sayani A.P., Chien, Y.W. Systemic delivery of peptides and proteins across absorptive mucosae.// Crit. Rev. Ther. Drug Carrier Syst. 1996. — V. 13. — p. 85 184.
- Boll M., Herget M., Wagener M. et. al. Expression cloning and functional characterization of the kidney cortex high-affinity proton-coupled peptide transporter.// Proc. Natl. Acad. Sci. USA. 1996. — V. 93. — p. 284−289.
- Fei Y.J., Kanai Y., Nussberger S. et. al. Expression cloning of a mammalian proton-coupled oligopeptide transporter.// Nature. 1994. — V. 368. — p. 563−566.
- Groneberg D.A. Expression, localization and functional aspects of the peptide transporter PEPT2 in the normal respiratory tract and in cystic fibrosis.// Pneumologie. -2003. V. 57.-p. 104−105.
- Groneberg D.A., F. Doring, H. Daniel, A. Fischer. Distribution of the oligopeptide transporter PEPT2 in normal human lung.// Am. J. Respir. Crit. Care Med. -2000. V. 161.-p. A150.
- Sugawara M.W., Huang Y.J., Fei F.H. et. al. Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2.// J. Pharm. Sci. -2000.-V. 89.-p. 781−789.
- Hirai S., Yashiki Т., Matsuzawa Т., Mima H. Absorption of drugs from the nasal mucosa of rat. // Int. J. Pharm. 1981. — V. 7. — p. 317.
- Pontiroli A. E. Peptide hormones: Review of current and emerging uses by nasal delivery.// Adv. Drug Deliv. Reviews. 1998. — V. 29. — p. 81 -87.
- Ben-Yedidia Т., Tarrab-Hazdai R., Schechtman D., Arnon R. Intranasal Administration of Synthetic Recombinant Peptide-Based Vaccine Protects Mice from Infection by Schistosoma mansoni.// Infect. Immun. 1999. — V. 67, № 9. — p. 43 604 366.
- Talegaonkar S., Mishra P.R. Intranasal delivery: An approach to bypass the blood brain barrier.// Indian J. Pharmacol. 2004. — V. 36. — p. 140−147.
- O’Hagan D.T., Critchley H., Faraj N.F. et al. Nasal absorption enhancers for biosynthetic human growth hormone in rats.// Pharm. Res. 1990. — V. 7. — p. 772−6.
- Eppstein D.A., Longenecker J.P. Alternative delivery sytems for peptides and proteins as drugs.// Crit. Rev. Ther. Drug Carrier Syst. 1988. — V. 5. — p. 99−139.
- Lawrence D. Intranasal delivery could be used to administer drugs directly to the brain.// Lancet. 2002. — V. 359, № 9318. — p. 1674.
- Graff C.L., Pollack G.M. P-Glycoprotein Attenuates Brain Uptake of Substrates After Nasal Instillation.// Pharm. Res. 2003. — V. 20, № 8. — p. 12 251 230.
- Graff C.L., Pollack G.M. Nasal drug administration: potential for targeted central nervous system delivery.// J. Pharm. Sci. 2005. — V. 94. — p. 1187−1195.
- Mitragotri S., Blankschtein D., Langer R.// Ultrasound-Mediated Transdermal Protein Delivery Science. 1995. -V. 269. — p. 850−853.
- Panchagnula R., Bindra P., Kumar N.et. al. Stability of insulin under iontophoretic conditions.// Pharmazie. 2006. — V. 61. — p. 1014−1018.
- Chang S.L., Hofmann G.A., Zhang L. et. al. Transdermal iontophoretic delivery of salmon calcitonin.// Int. J. Pharm. 2000. — V. 200. — p. 107−113.
- Benson H.A.E., Namjoshi S. Proteins and peptides: strategies for delivery to and across the skin.// J. Pharm. Sci. 2008. — V. 97. — p. 3591−3610.
- Reddy K. Ocular Therapeutics and Drug Delivery: A Multi-disciplinary Aapproach.// CRC Press. 1995. — pp. 587.
- Chiou G.C. Systemic delivery of polypeptide drugs through ocular route. // Annu. Rev. Pharmacol. Toxicol. 1991. — V. 31. — p. 457−467.
- Kansara V., Hao Y., Mitra A.K. Dipeptide monoester ganciclovir prodrugs for transscleral drug delivery: targeting the oligopeptide transporter on rabbit retina.// J. Ocul. Pharmacol. Ther. 2007. — V. 23. — p. 321−334.
- De Groot A.N., Vree T.B., Hekster Y.A. et. al. Bioavailability and pharmacokinetics of sublingual oxytocin in male volunteers.// J. Pharm. Pharmacol. -1995.-V. 47.-p. 571−575.
- Modi P., Mihic M., Lewin A. The evolving role of oral insulin in the treatment of diabetes using a novel RapidMist (trade mark) System.// Diabetes Metab. Res. Rev. 2002. — V. 18. — p. 38−42.
- Goldberg M., Gomez-Orellana I. Challenges for the oral delivery of macromolecules.// Nat. Rev. Drug. Discov. 2003. — V. 2. — p. 289−295.
- Jaehde U., Masereeuw R., Deboer A.G. et. al. Quantification and Visualization of the Transport of Octreotide, a Somatostatin Analog, across Monolayers of Cerebrovascular Endothelial-Cells.// Pharmaceutical Research. 1994. — V. 11., № 3. p. 442−448.
- Hilgendorf C., Ahlin G., Seithel A. et. al. Expression of 36 drug transporter genes in human intestine, liver, kidney, and organotypic cell lines.// Drug. Metab. Dispos. 2007. — V. 35. — p. 1333−1340.
- Lee Y., Sinko P. Oral delivery of salmon calcitonin.// Adv. Drug. Deliv. Rev. -2000. V. 42, № 3. — p. 225−38.
- Fricker G., Drewe J. Current concepts in intestinal peptide absorption.// J. Pept. Sci. 1996. — V. 2.-p. 195−211.
- Cleary J.D., Taylor J.W. Enalapril: a new angiotensin converting enzyme inhibitor.// Drug Intelligence and Clinical Pharmacy. 1987. — V. 20, № 3. — p. 177 186.
- Meisel S., Shamiss A., Rosenthal T. Clinical pharmacokinetics of ramipril.// Clin. Pharmacokinet. 1994. — V. 26, № 1. — p.7−15.
- Gustafsson D., Nystrom J., Carlsson S. et. al. The Direct Thrombin Inhibitor Melagatran and Its Oral Prodrug H 376/95: Intestinal Absorption Properties,
- Biochemical and Pharmacodynamic Effects.// Thromb. Res. 2001. — V. 101. — p. 171−181.
- Gustafsson D. Oral Direct Thrombin Inhibitors in Clinical Development.// J. Intern. Med. 2003. — V. 254. — p. 322−334.
- Newey H., Smyth D.H. The intestinal absorption of some dipeptides.// J. Physiol. 1959. — V. 145. — p. 48−56.
- Milne M.D. Disorders of intestinal amino acid transport.// J. Clin. Pathol. -1971. V. 24, suppl. 5. — p. 41−44.
- Adibi S.A. The oligopeptide transporter (Pept-1) in human intestine: biology and function.// Gastroenterology. 1997. — V. 113. — p. 332−340.
- Ganapathy V., Leibach F.H. Is intestinal peptide transport energized by a proton gradient?// Am. J. Physiol. Gastrointest. Liver Physiol. 1985. — V. 249. — p. G153-G160.
- Liang R., Fei Y.J., Prasad P.D. et. al. Human intestinal H+/peptide cotransporter. Cloning, functional expression, and chromosomal localization.// J. Biol. Chem. 1995. — V. 270. — p. 6456−6463.
- Mackenzie В., Fei Y.J., Ganapathy V., Leibach F.H. The human intestinal H+/oligopeptide cotransporter hPEPTl transports differently-charged dipeptides with identical electrogenic properties.// Biochim. Biophys. Acta. 1996. — V. 1284. — p. 125−128.
- Mackenzie В., Loo D.D.F., Fei Y. et. al. Mechanisms of the human intestinal H±coupled oligopeptide transporter hPEPTl.// J. Biol. Chem. 1996. — V. 271. — p. 5430−5437.
- Sala-Rabanal M., Loo D.D.F., Hirayama B.A., Turk E., Wright E.M. Molecular interactions between dipeptides, drugs and the human intestinal H+ -oligopeptide cotransporter hPEPTl.// J. Physiol. 2006. — V. 574. — p. 149−166.
- Daniel H. Molecular and integrative physiology of intestinal peptide transport.// Annu. Rev. Physiol. 2004. — V. 66. — p. 361−384.
- Ganong W.F. Section V. Gastrointestinal function. In V. Vermeirssen et al. Review of Medical Physiology. 1997. — p. 437−481.
- Ganapathy V., Leibach F.H. Human intestinal H+/peptide cotransporter. Cloning, functional expression, and chromosomal localization.// J. Biol. Chem. -1995. V. 270. — p. 6456−6463.
- Ganapathy M.E., Brandsch M., Prasad P. et. al. Differential recognition of beta -lactam antibiotics by intestinal and renal peptide transporters, PEPT 1 and PEPT 2.// J. Biol. Chem. 1995. — V. 270. — p. 25 672−25 677.
- Ganapathy M.E., Prasad P.D., Mackenzie B. et. al. Interaction of anionic cephalosporins with the intestinal and renal peptide transporters PEPT 1 and PEPT 2.// Biochim. Biophys. Acta. 1997. — V. 1324. — p. 296−308.
- Terada Т., Saito H., Mukai M., Inui K. Recognition of beta-lactam antibiotics by rat peptide transporters, PEPT1 and PEPT2, in LLC-PK1 cells.// Am. J. Physiol. -1997. V. 273. — p. F706-F711.
- Inui К., Tomita Y., Katsura Т., et. al. H+ coupled active transport of bestatin via the dipeptide transport system in rabbit intestinal brush-border membranes.// J. Pharmacol. Exp. Ther. 1992. — V. 260. — p. 482−486
- Ни M., Borchardt R.T. Mechanism of L-alpha-methyldopa transport through a monolayer of polarized human intestinal epithelial cells (Caco-2).// Pharm. Res. -1990. V. 7. — p. 1313−1319.
- Ganapathy M.E., Huang W., Wang H., et. al. Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2.// Biochem. Biophys. Res. Commun. 1998. — V. 246. — p. 470−475.
- Boll M., Markovich D., Weber W.M. et. al. Expression cloning of a cDNA from rabbit small intestine related to proton-coupled transport of peptides, beta-lactam antibiotics and ACE-inhibitors.// Pflugers .Arch. 1994. — V. 429. — p. 146 149.
- Zhu Т., Chen X.Z., Steel A. et. al. Differential recognition of ACE inhibitors in Xenopus laevis oocytes expressing rat PEPT1 and PEPT2.// Pharm. Res. 2000. — V. 17.-p. 526−532.
- Kntitter I., Wollesky C., Kottra G. et. al. Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited.// J. Pharmacol. Exp. Ther. -2008.-V. 327.-p. 432−441.
- Anand В., Nashed Y., Mitra A. Novel dipeptide prodrugs of acyclovir for ocular herpes infections: Bioreversion, antiviral activity and transport across rabbit cornea.// Curr. Eye Res. 2003. — V. 26. — 151−163.
- Rousselle С., Clair P., Lefauconnier J.M. et. al. New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy.// Mol. Pharmacol. 2000. — V. 57. — p. 679−686.
- Pardridge W.M. The Blood-Brain Barrier: Bottleneck in Brain Drug Development.// The Journal of the American Society for Experimental NeuroTherapeutics. 2005. — V. 2. — p. 3−14.
- Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approach to estimate solubility and permeability in drug discovery and development settings.// Adv. Drug Deliv. Rev. 1997. — V. 23. — p. 3−25.
- Egleton R.D., Davis T.P. Development of Neuropeptide Drugs that Cross the Blood-Brain Barrier.// The Journal of the American Society for Experimental NeuroTherapeutics. 2005. — V. 2. — p. 44−53.
- Banks W.A., Kastin A.J., Michals E.A., Barrera C.M. Stereospecific transport of Tyr-MIF-1 across the blood- brain barrier by peptidetransport system-1.// Brain. Res. Bull. 1990. — V. 25. — p. 589- 592.
- Yamashita Т., Shimada S., Guo W., et. al. Cloning and functional expression of a brain peptide/histidine transporter.// J. Biol. Chem. 1997. — V. 272. — p. 1 020 510 211.
- Sakata K., Yamashita Т., Maeda M., Moriyama Y., Shimada S. Cloning of a lymphatic peptide/histidine transporter.// Biochem. J. 2001. — V. 356. — p. 53−60.
- Wang H., Fei Y.J., Ganapalhy V., Leibach F.H. Electrophysiological characteristics of the proton-coupled peptide transporter PEPT2 cloned from rat brain.// Am. J. Physiol. 1998. — V. 275. — p. C967-C975.
- Novotny A., Xiang J., Stummer W. et. al. Mechanisms of 5-aminolevulinic acid uptake at the choroid plexus.// J. Neurochem. 2000. — V. 75. — p. 321−328.
- Tcuscher N.S., Novotny A., Keep R.F., Smith D.E. Functional evidence for presence of PEPT2 in rat choroid plexus: studies with glycylsarcosine.// J. Pharmacol. Exp. Ther. 2000. — V. 294. — p. 494−499.
- Shen Hi, Keep R. F, Hu Y., Smith D.E. PEPT2 (S.cl5a2)-mediated unidirectional transport of cefadroxil from cerebrospinal fluid into choroid plexus.// J. Pharmacol. Exp. Ther. 2005. — 315. — p. 1101−1108.
- Агафонов A.A., Пиотровский В. К. Программа M-IND оценки системных параметров фармакокинетики модельно-независимым методом статических моментов.//Хим.-Фарм. Журн.—1991.—№. 10.—С. 16−19.
- Lee V., Yamamoto A. Penetration and enzymatic barriers to peptide and protein absorption.// Adv. Drug Delivery Rev. 1990. — V. 4. — p. 171−207.
- Hu L. Prodrugs: Effective Solutions for Solubility, Permeability and Targeting Challenges.// Meeting Report Prodrugs. 28−29 June, USA. 2004. — p. 52.
- Abbot P.J. Neotame.// WHO Food Additives. 2004. — Series № 52. — p. 1−45.
- N. Aronin, R.E. Carraway, C.G. Ferris et al. The stability and metabolism of intravenously administered neurotensin in the rat.// Peptides. 1982. — V. 3, № 4. -p. 637−642.
- Machida R., Tokumura Т., Tsuchiya Y. et al. Pharmacokinetics of novel hexapeptides with neurotensin activity in rats.// Biol. Pharm. Bull. 1993. — V. 16. -p. 43−47.
- Garsia- Garayoa E., Blauenstein P., Bruehmeier M. et al. Preclinical Evaluation of a New, Stabilized Neurotensin (8−13) Pseudopeptide Radiolabeled with 99mTc.// J. Nuclear Medicine. 2002. — V. 43. — p. 374−383.
- Островская Р.У., Крупина H.A., Гудашева T.A., Середенин С. Б. Эксперимент, и клин. Фармакология, в печати.
- Гузеватых JI.C., Емельянова Т. Г., Зайцева Н. И. и соавт.// Известия АН. Серия биологическая. 2004. — Т. 4. — с. 488−492.
- Pajouhesh H., Lenz G.R. Medicinal Chemical Properties of Successful Central Nervous System Drugs.// The Journal of the American Society for Experimental NeuroTherapeutics. 2005. — V. 2. — p. 541−553.
- Li W., Escarpe P.A., Eisenberg E.J. et. al. Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071.// Antimicrob. Agents Chemother. 1998. — V. 42. — p. 647−653.
- Danks M.K., Potter P.M. Enzyme-prodrug systems. In: Springer CJ, editor. Suicide gene therapy: Methods and reviews. Totowa: Humana Press Inc. 2003. — p. 247−262.
- Hosokawa M., Maki Т., Satoh T. Characterization of molecular species of liver microsomal carboxylesterases of several animal species and humans.// Arch. Biochem. Biophys. 1990. — V. 277. — p. 219−227.
- Satoh Т., Hosokawa M., Atsumi R. et. al. Metabolic activation of CPT-11, 7-ethyl-10−4-(l-piperidino)-l- piperidino. carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase.// Biol. Pharm. Bull. 1994. — V. 17. — p. 662 664.
- Yoshigae Y., Imai Т., Horita A., Matsukane H., Otagiri M. Species differences in stereoselective hydrolase activity in intestinal mucosa.// Pharm. Res. 1998. — V. 15.-p. 626−631.
- McCracken N.W., Blain P.G., Williams F.M. Human xenobiotic metabolizing esterases in liver and blood.// Biochem. Pharmacol. 1993. — V. 46. — p. 1125- 1129.
- Yang J.Z., Chen W., Borchardt R.T. In vitro stability and in vivo pharmacokinetic studies of a model opioid peptide, H-Tyr-D-Ala-Gly-Phe- D-Leu-OH (DADLE), and its cyclic prodrugs.// J. Pharmacol. Exp. Ther. 2002. — V. 303. -p. 840−848.
- Liederer B.M., Borchardt R.T. Stability of oxymethyl-modified coumarinic acid cyclic prodrugs of diastereomeric opioid peptides in biological media fromvarious animal species including human.// J. Pharm. Sci. 2005. — V. 94. — p. 21 982 206.
- Satoh Т., Hosokawa M. The mammalian carboxylesterases: From molecules to functions.// Annu. Rev. Pharmacol. Toxicol. 1998. — V. 38. — p. 257−288.
- Beaumont K., Webster R., Gardner I., Dack K. Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: Challenges to the discovery scientist.// Curr. Drug. Metab. 2003. — V. 4. — p. 461185.